Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Karo Pharma AB (publ)
  6. Summary
    KARO   SE0007464888

KARO PHARMA AB (PUBL)

(KARO)
  Report
Delayed Quote. Delayed Nasdaq Stockholm - 05/27 11:29:37 am
56.3 SEK   +1.08%
04/19Karo Pharma to Raise $262 Million in Rights Issue
MT
04/19Karo Pharma's rights issue fully subscribed
AQ
04/12Karo Pharma publishes the 2021 annual report
AQ
 SummaryQuotesChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
05/20/2022 05/23/2022 05/24/2022 05/25/2022 05/27/2022 Date
56.4(c) 56.1(c) 55.7(c) 55.7(c) 56.3(c) Last
34 432 69 046 81 025 51 995 61 651 Volume
+0.36% -0.53% -0.71% 0.00% +1.08% Change
More quotes
Estimated financial data (e)
More Financials
Company
Karo Pharma AB, formerly known as Karo Bio AB, is a Sweden-based biopharmaceutical company engaged in the research and development of drugs based on the nuclear receptors. The Company’s pipeline comprises three projects: Estrogen Receptor Beta (ERbeta) cancer, a platform, which focuses on the development of ERbeta in cancer treatment; ERbeta multiple sclerosis (MS), which specializes in the autoimmune disease MS... 
Read more
Sector
Pharmaceuticals
Calendar
07/20Earnings Release
More about the company
All news about KARO PHARMA AB (PUBL)
04/19Karo Pharma to Raise $262 Million in Rights Issue
MT
04/19Karo Pharma's rights issue fully subscribed
AQ
04/12Karo Pharma publishes the 2021 annual report
AQ
04/04Karo Pharma completes the acquisition of the E45 brand from Reckitt
AQ
04/01Reckitt Completes Sale of E45 Brand to Karo Pharma
MT
04/01Karo Pharma completes the acquisition of the E45® brand from Reckitt
AQ
03/28KARO PHARMA AB (OM : KARO) acquired Del Decus Enterprises Ltd.
CI
03/24KARO PHARMA AB(OM : KARO) dropped from OMX Nordic All-Share Index
CI
03/23Karo Pharma publishes prospectus relating to the rights issue and receives approval to ..
AQ
03/23Karo Pharma Receives Approvals For $265 Million Rights Issue, Change Of Listing To Nasd..
MT
03/22KARO PHARMA AB (PUBL) : RIGHTS ISSUE: 3 new shares @ 52 SEK for 14 existing shares
FA
03/16Karo Pharma To Initiate $262 Million Rights Issue To Repay Bridge Loan
MT
03/16Karo Pharma resolves on a fully guaranteed rights issue of approximately SEK 2.5 billio..
AQ
03/10Nasdaq Stockholm Approves Delisting Application From Karo Pharma
MT
03/10Karo Pharma receives approval to delist the Company's share from Nasdaq Stockholm in co..
AQ
More news
News in other languages on KARO PHARMA AB (PUBL)
04/19Karo Pharma lève 262 millions de dollars dans le cadre d'une émission d'actions.
04/01Reckitt conclut la vente de la marque E45 à Karo Pharma
03/28KARO PHARMA AB (PUBL) (OM : KARO) a acquis Del Decus Enterprises Ltd.
03/23Karo Pharma reçoit les approbations pour une émission de droits de 265 millions de doll..
03/10Nasdaq Stockholm approuve la demande de radiation de Karo Pharma
More news
Analysis
Reckitt to sell E45 skincare brand to Karo Pharma for $268 mln
Chart KARO PHARMA AB (PUBL)
Duration : Period :
Karo Pharma AB (publ) Technical Analysis Chart | KARO | SE0007464888 | MarketScreener
Technical analysis trends KARO PHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Managers and Directors
Christoffer Lorenzen Chief Executive Officer
Jon Johnsson Chief Financial Officer
Bo Jesper Hansen Chairman
Sofia Pedersen Vice President-Scientific Affairs
Håkan Åström Independent Director
Sector and Competitors
1st jan.Capi. (M$)
KARO PHARMA AB (PUBL)-5.64%1 564
JOHNSON & JOHNSON5.86%476 521
PFIZER, INC.-8.70%302 483
ELI LILLY AND COMPANY17.11%291 184
ROCHE HOLDING AG-13.00%281 098
ABBVIE INC.10.78%265 067